Prevalence of nonalcoholic fatty liver disease in a Spanish town: A population-based study

被引:0
|
作者
Cusacovich, I. [1 ]
Sanchez-Lite, I. [3 ]
Toribio, B. [3 ]
Gonzalez, J. M. [2 ,6 ]
Perez-Rubio, A. [4 ]
Andaluz-Ojeda, D. [5 ]
机构
[1] Hosp Clin Univ Valladolid, Serv Med Interna, Valladolid, Spain
[2] Hosp Clin Univ Valladolid, Serv Gastroenterol & Hepatol, Valladolid, Spain
[3] Hosp Clin Univ Valladolid, Serv Radiol, Valladolid, Spain
[4] Hosp Clin Univ Valladolid, Serv Epidemiol, Valladolid, Spain
[5] Hosp Clin Univ Valladolid, Unidad Cuidados Intens, Valladolid, Spain
[6] Ctr Hospitalier Monkole, Serv Gastroenterol & Hepatol, Kinshasa, DEM REP CONGO
来源
REVISTA CLINICA ESPANOLA | 2023年 / 223卷 / 07期
关键词
Prevalence; Nonalcoholic fatty liver disease; Metabolic-associated fatty liver disease; Nonalcoholic steatohepatitis; Fatty liver; ADULT-POPULATION; NATURAL-HISTORY; ASSOCIATION; CIRRHOSIS; ETIOLOGY; METABOLISM; DIAGNOSIS; SPECTRUM; FIBROSIS; TESTS;
D O I
10.1016/j.rce.2023.04.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Nonalcoholic fatty liver disease (NAFLD) is western countries' most important cause of hepatic steatosis and hypertransaminasemia. The objective was to evaluate the prevalence of NAFLD among 261,025 people in the East Valladolid public healthcare area in Spain. Methods: We randomly selected 1800 participants from a public healthcare system card data-base, representing most of the population. We performed a medical record, measurement of anthropometric parameters, abdominal ultrasound, and blood tests to rule out hepatic disease in all patients. We calculated the FLI score in all patients. Results: Four hundred and forty-eight participants agreed to participate in the study. The pre-valence of nonalcoholic fatty liver disease in our study was 22.3% [18.5--26.2%]. Prevalence was highest between 50 and 70 years, increasing with age (p < 0.006). There were no significant differences in sex (p = 0.338). The median body mass index was 27.2, and NAFLD was related to the weight (p < 0.001) and abdominal perimeter (p < 0.001). Logistic regression analysis showed GGT lower than 26 UI/ml, body mass index higher than 31, and HOMA IR greater than 2.54 as independent factors to predict NAFLD in the sample. NAFLD diagnosis matched with an elevated FLI score in 88% of cases. Conclusion: According to other epidemiological studies, NAFLD's prevalence is very high. A complete study with a clinical consultation, image studies, and blood tests in all patients allows us to assess the prevalence of NAFLD in the population. & COPY; 2023 Elsevier Espana, S.L.U. and Sociedad Espanola de Medicina Interna (SEMI). All rights reserved.
引用
收藏
页码:396 / 404
页数:9
相关论文
共 50 条
  • [31] NONALCOHOLIC FATTY LIVER DISEASE IS NOT ASSOCIATED WITH COGNITIVE IMPAIRMENT IN ELDERLY: RESULTS OF A POPULATION-BASED STUDY
    Koehler, Edith
    Schouten, Jeoffrey N.
    Schrijvers, Elisabeth M.
    Hansen, Bettina E.
    Hofman, Albert
    Stricker, Bruno H.
    Ikram, Mohammad A.
    Janssen, Harry L.
    HEPATOLOGY, 2011, 54 : 1126A - 1126A
  • [32] Glycemic variability and the risk of nonalcoholic fatty liver disease : A nationwide population-based cohort study
    Hong, So-hyeon
    Lee, Ji Sung
    Kim, Jung A.
    Lee, You-Bin
    Roh, Eun
    Yu, Ji Hee
    Kim, Nam Hoon
    Yoo, Hye Jin
    Seo, Ji A.
    Kim, Sin Gon
    Kim, Nan Hee
    Baik, Sei Hyun
    Choi, Kyung Mook
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 177
  • [33] Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study
    Cleveland, Erin R.
    Ning, Hongyan
    Vos, Miriam B.
    Lewis, Cora E.
    Rinella, Mary E.
    Carr, John Jeffrey
    Lloyd-Jones, Donald M.
    VanWagner, Lisa B.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2019, 34 (12) : 2772 - 2778
  • [34] Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study
    Erin R. Cleveland
    Hongyan Ning
    Miriam B. Vos
    Cora E. Lewis
    Mary E. Rinella
    John Jeffrey Carr
    Donald M. Lloyd-Jones
    Lisa B. VanWagner
    Journal of General Internal Medicine, 2019, 34 : 2772 - 2778
  • [35] Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study
    VanWagner, Lisa B.
    Wilcox, Jane E.
    Colangelo, Laura A.
    Lloyd-Jones, Donald M.
    Carr, J. Jeffrey
    Lima, Joao A.
    Lewis, Cora E.
    Rinella, Mary E.
    Shah, Sanjiv J.
    HEPATOLOGY, 2015, 62 (03) : 773 - 783
  • [36] DIET QUALITY AND ITS ASSOCIATION WITH NONALCOHOLIC FATTY LIVER DISEASE AND MORTALITY - A POPULATION-BASED STUDY
    Yoo, Eric
    Li, Andrew
    Cholankeril, George
    Kim, Donghee
    Ahmed, Aijaz
    HEPATOLOGY, 2019, 70 : 726A - 726A
  • [37] A Prediction Model of the Incidence of Nonalcoholic Fatty Liver Disease With Visceral Fatty Obesity: A General Population-Based Study
    Zhou, Yang
    Chai, Xiangping
    Guo, Tuo
    Pu, Yuting
    Zeng, Mengping
    Zhong, Aifang
    Yang, Guifang
    Cai, Jiajia
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [38] PREVALENCE AND FACTORS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA IN CIRRHOTIC AND NON-CIRRHOTIC NONALCOHOLIC FATTY LIVER DISEASE PATIENTS: A POPULATION-BASED STUDY
    Pinyopornpanish, Kanokwan
    Khoudari, George
    Abou Saleh, Mohannad
    Mansoor, Emad
    Angkurawaranon, Chaisiri
    Sarmini, Muhammad Talal
    McCullough, Arthur
    GASTROENTEROLOGY, 2020, 158 (06) : S1415 - S1415
  • [39] Antibiotic use and development of nonalcoholic fatty liver disease: A population-based case-control study
    Ebrahimi, Fahim
    Simon, Tracey G.
    Hagstrom, Hannes
    Sun, Jiangwei
    Bergman, David
    Forss, Anders
    Roelstraete, Bjorn
    Engstrand, Lars
    Ludvigsson, Jonas F.
    LIVER INTERNATIONAL, 2023, : 2186 - 2197
  • [40] Short Sleep Duration is a Risk of Incident Nonalcoholic Fatty Liver Disease: A Population-based Longitudinal Study
    Okamura, Takuro
    Hashimoto, Yoshitaka
    Hamaguchi, Masahide
    Obora, Akihiro
    Kojima, Takao
    Fukui, Michiaki
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2019, 28 (01) : 73 - 81